Human papillomavirus (HPV) is the primary cause of human cervical cancer. The viral proteins E6 and E7 are essential to transform non-cancerous epithelial cells into cancerous carcinomas by targeting key tumour suppressors p53 and retinoblastoma proteins, respectively, but the cellular factors involved in E6 and E7 transcription themselves are incompletely understood. In this study, we defined a novel isoform of the Mixed Lineage 
Introduction
Cervical cancer is a major cause of death among women worldwide. Over 90 % of cervical cancers are related to the human papillomavirus virus (HPV) infections, implicating its role as the causative agent in cervical cancer (1, 2) . A common feature among cervical cancers is the selective up-regulation of two HPV oncogenes, namely E6 and E7, which encode for multifunctional proteins that are known for their abilities to inactivate cellular tumour repressors, p53 and pRb, respectively (3, 4) . It has been shown that E6 and E7 expressions in cells may lead to genomic instability, a hallmark of cancer development (5) . In addition, cell cycle arrest and checkpoints are de-regulated in these cells, due to the loss of tumour suppressors p53 and pRb (4) . These two oncoproteins are translated from a bicistronic mRNA under the control of the HPV long control region (LCR), located upstream of the E6 open reading frame (6) (7) (8) . Despite extensive studies carried out to elucidate the regulatory property of LCR which involves a complex system of both viral and human transcription factors, a complete understanding of the mechanism is yet to be achieved (9) (10) (11) . Leukemia 5) gene was first discovered during the search for candidate myeloid leukaemia tumour suppressor genes from a commonly deleted 2.5 Mb segment within chromosome band 7q22 (12, 13) . MLL5 lacks DNA binding motifs of A-T hooks as well as the methyltransferase homology motifs that are commonly found in other MLL protein members. These may suggest that MLL5 does not bind directly to DNA but instead modulates transcription indirectly via protein-protein interactions through its PHD and SET domains (13) . Even though the other MLL family members are known to involved in histone suggested that a short N-terminal isoform of MLL5 (608 amino acids) with both the PHD and SET domain possesses GlcNAcylation-dependent HKMT activity (18) . Furthermore, studies reported role of MLL5 in histone modifying through indirect mechanism or forming complexes (19, 20) . Three independent studies reported the genetic analysis of Mll5 deficiency in mice which suffer from mild growth retardation but do not develop spontaneous leukemia (17, 21, 22) . However, a recent clinical study reported that higher MLL5 expression levels were associated with better prognosis in acute myeloid leukemia (23) . We have previously shown that over-expression or knockdown of MLL5 impeded cell cycle progression and proposed that MLL5 may participate in the cell cycle regulatory network at multiple stages of the cell cycle (24, 25) . We demonstrated that MLL5 is a substrate of Cdc2 kinase and phosphorylation of MLL5 is required for mitosis progression (26) .
MLL5 (Mixed Lineage
During the course of studying the restoration of p53 protein and reduction of Rb phosphorylation upon knockdown of MLL5, we found an intriguing link between the downregulation of E6/E7 oncoproteins and MLL5 levels in HPV16/18-postive cervical cancer cell lines. We further characterized a novel MLL5 isoform which plays a role in activating E6/E7 through the association with the AP-1 transcription factor in HPV-LCR. The novel role of MLL5 isoform in cervical cancer makes it a potential therapeutic target and a biomarker for human cervical cancers. 
Materials and Methods
Cell culture and transfection. Human cervical carcinoma SiHa (HPV16+), HeLa (HPV18+) and C33A (HPV negative), embryonic kidney cells HEK293T were cultured as monolayer in Dulbecco's Modified Eagles Medium (DMEM, Gibco) while human cervical carcinoma Caski in Roswell Park Memorial Institute 1640 (RPMI, Gibco) respectively. The respective mediums were supplemented with 10% fetal bovine serum (FBS, Hyclone), 2 mM glutamine (Gibco) and 100 units/ml penicillin/streptomycin (Gibco) at 37 ºC with 5 % CO 2 . Plasmid transfection was carried out using TransIT-LT1 transfection reagent (Mirus, USA) according to the product manual.
Rapid amplification of cDNA ends. Putative MLL5 isoform was cloned using SMARTer™ RACE cDNA Amplification kit (Clontech, USA) according to the product manual. PolyA+ mRNA was extracted using Oligotex Direct mRNA Midi Kit (Qiagen, USA) and used as templates for both 5' and 3'-RACE. Gene-specific primers used for both 5'and 3'-RACE recognized exon 7 of MLL5 and are as follow: 5primeM5.rev (5'-TTTCCCTTTTCCGGCGTTGT) and 3primeM5.for (5'-CAACGCCGGAAAAGGGAAAAT). RACE products were cloned into pCR2.1-TOPO (Invitrogen, USA) for sequencing.
Plasmid construction. FLAG-MLL5-CT (amino-acid 1113 to 1858) was previously constructed (26) . GFP-tagged MLL5 C-terminal vector (GFP-CT) was generated by cloning MLL5 C-terminal region into pEGFP-C1 (Clontech) in frame with SalI and BamHI. PCR amplicons were digested with BamHI and NotI and cloned into pEF6/V5-His vector (Invitrogen) for FLAG-MLL5ȕ; while digested with SalI and BamHI and cloned into pEGFP-C1 vector for GFP-MLL5ȕ. To generate constructs for luciferase assays for the LCR promoter activity, a 958 bp (nucleotides 7091 to 119) fragment containing the LCR and p-105 promoter was cloned into pGL3-basic (Promega) with XhoI and HindIII sites. Deletion constructs were generated in a similar manner using appropriately designed primers. Mutant constructs were generated using the Quick Change site-directed mutagenesis kit (Stratagene). Patients were informed and agreed to the use of their biological sample for scientific research in accordance with Singapore regulations. Total RNA and genomic DNA were extracted from the samples by using TRIzol and Wizard Genomic DNA Purification Kit (Promega).
Dual luciferase assays.
A dual-luciferase reporter assay (Promega) was employed to measure the transcription activity of the promoter region in interest. HEK293T and HeLa cells were co-transfected with both pGL3 and pEGFP, along with pRL-TK as the internal control. Cells were then harvested 48 hours post-transfection and each sample was read in triplicate by using a luminometer (Tecan). Normalization of luciferase reading by renilla reading was performed before comparisons were made.
Chromatin Immunoprecipitation. FLAG-MLL5ȕ or FLAG-CT were transfected into HeLa cells for 48 hours before cells were being harvested for ChIP as described previously (27) except the modification in the sonication step. ( Figure 1D ). Nonetheless, a small but detectable amount of p53 protein was observed in MLL5-siRNA#4-knocked down samples, which could be attributed to the effect of fulllength MLL5 knockdown as seen in our previous observations (25) . Next, we attempted to discern the effect of MLL5-knockdown with MLL5-siRNA#1 and #4 on both E6 and E7 mRNA levels. A marked down-regulation of both E6 and E7 mRNA was observed in all three HPV-positive cell lines when MLL5-siRNA#1 was used but not MLL5-siRNA#4 despite the comparable knockdown efficiency of both siRNAs on MLL5 mRNA ( Figure 1E ).
The role of E2 which is a known E6/E7 repressor was disregarded, since E2 was shown to be absent in these HPV-positive cells due to the disruption of E2 gene upon the integration of HPV DNA (28) . These observations led us to speculate that a putative MLL5 isoform comprising the N-terminal region but lacking the central and C-terminal regions may be present.
Characterization of the novel MLL5 isoform
To validate our hypothesis, 5' and 3' Rapid Amplification of cDNA Ends (RACE) were carried out to identify the isoform. 
MLL5β is responsible for the restoration of p53 protein level through down-regulation of E6 and E7 transcripts
We employed anti-MLL5-227 antibody, raised against the N-terminal region of MLL5 (amino acid 227-241), to probe for the MLL5β (24) . A protein band migrating at approximate 70-kDa was successfully knocked down by both MLL5-siRNA#1 and #2 but not MLL5-siRNA#3 and #4 ( Figure 3A) . Importantly, knockdown of the 70-kDa MLL5ȕ protein corresponded to the restoration of p53 level. Next, a new siRNA duplex that specifically targets the 26-bp sequence exclusively found in MLL5ȕ mRNA, designated as MLL5ȕ- siRNA, was synthesized. MLL5ȕ was successfully knocked down and this corresponded to an increase in p53 protein level ( Figure 3B ). Besides that, we performed similar knockdown experiment on HPV-negative cells HCT116 and U2OS and confirmed that p53 accumulation only occurs in HPV-positive cells (Supplementary Figure S2) . Consistent with our hypothesis, the E6/E7 levels were found to be significantly reduced in all three human cervical cancer cell lines when MLL5β-siRNA was used ( Figure 3C ). It is noteworthy that exogenously expressed GFP-MLL5ȕ in HeLa cells has no effects on the expressions of E6 and E7 transcript (Supplementary Figure S3) . Subsequently, we asked whether exogenous expression of MLL5β can abrogate the MLL5ȕ-siRNA-mediated p53 restoration. Effect of p53 restoration when knocked down with MLL5ȕ-siRNA was rescued when GFP-MLL5ȕ was over-expressed but not GFP-tagged full-length MLL5 (GFP-MLL5-FL) ( Figure 3D ). GFP-MLL5β plasmid was mutated appropriately (indicated by asterisk) so that the expression cannot be inhibited by MLL5ȕ-siRNA.
MLL5ȕ activates HPV18 E6/E7 transcription through the regulation of LCR
Previous studies have shown that proteins such as epidermal growth factor and interferon regulator factor-2 are able to regulate E6/E7 gene transcription through regulatory region, termed long control region (LCR) or upstream regulatory region (URR) (29, 30) Figure S5) . Besides this, we have shown that the amount of HPV18-LCR is the limiting factor for MLL5β-mediated E6/E7 activation as an increase in relative luciferase activity can be observed when an increasing concentration of pGL3-HPV18-LCR was used (Supplementary Figure S6) . 
Next, we constructed various fragments of HPV18-LCR with pGL3 vector to dissect the region responsible for LCR activation through association with MLL5ȕ. As shown in Figure   4B and Supplementary Figure S4 , relative luciferase activity of fragment A in both HEK293T cells and HeLa cell lines exhibited the largest decrease, suggesting that the distal region from nucleotides 7018 to 7305 of LCR contains the essential elements required for the activation of HPV18-LCR by MLL5ȕ.
To demonstrate that MLLȕ would interact with HPV18-LCR to regulate its transcriptional activity, chromatin immunoprecipitation (ChIP) experiment was set up in HeLa cells.
Significant enrichment of the amplicon using primer pair 2 was observed in the Į-FLAG-MLL5β pulled-down eluates but not in the FLAG-MLL5-CT ( Figure 4C ), indicating an interaction between MLL5ȕ and HPV18-LCR.
AP-1 transcription factor binding site is essential in the MLL5ȕ-mediated activation of

HPV18-LCR
Since there is no conserved DNA-binding motif found on MLL5 and recent study has shown that MLL5 or its isoform (MLL5α, 608 amino acids) can form complex with other proteins to exert its H3K4 activity (13, 18, 19) , we hence hypothesized that one or more transcription factors might be involved in the MLL5ȕ-mediated E6/E7 gene activation. An in silico study using PROMO (32) virtual laboratory was first conducted to screen for putative transcription factor binding sites on the HPV18-LCR fragment amplified by primer pair 2. Four putative transcription factor binding sites with high matching scores were identified ( Figure 5A ). MLL5 lacks intrinsic H3K4 methyltransferase activity (15, 17), nonetheless, it contains a SET domain which possesses HKMT activity (33) . Moreover, four other MLL protein family members were found to exert H3K4 methyltransferase activity through their SET domain (15, 16, 34) . Therefore, to investigate whether MLL5ȕ activates E6/E7 transcription through the SET domain, SET-inactivated (Y358A) MLL5ȕ mutant was constructed and used in the dualluciferase assay (18) . Relative luciferase activity was found to decrease up to two fold when SET mutant was used ( Figure 5D ). Nonetheless, only a marginal decrease in the luciferase activity was observed when the concentration of exogenously-introduced SET mutant vector was increased. It is noteworthy that SET-inactivated MLL5ȕ mutant can still interact with Figure S10) . Although full-length MLL5 (1858 amino acids) has been shown to lack intrinsic histone methyltransferase H3K4 activity (15, 17); an isoform of MLL5 comprising a total of 608 amino acids with PHD and SET domain exhibited GlcNAcylation-dependent HKMT activity in retinoic acid-induced granulopoiesis (18) . Given the fact that viruses often cause diseases when they enter host cells and 'hijack' the important cellular apparatus to redirect the cellular functions for their benefit, it is possible that the induction of MLL5ȕ isoform may be an invasive strategy employed by HPV to regulate E6/E7 promoter activity ( Figure 6 ). MLL5ȕ interacts with AP-1 transcription factor and recognizes the AP-1 binding site on nucleotide 7326 of the distal region of LCR ( Figure 6, dashed area) . The SET domain in MLL5ȕ was found to play a role in the activation. However, when SET domain was inactivated, the effect of E6/E7 gene activation was not depleted completely ( Figure 5D Given that MLL5ȕ-siRNA was able to simultaneously reduce the E6/E7 transcripts, there is a greater potential for MLL5ȕ to serve as a novel specific therapeutic target for human cervical cancers than siRNA targeting E6 or E7 alone. Besides, the fact that MLL5ȕ can be detected only in HPV-positive cancer cells but not in normal diploid cells suggests that the potential side-effects of MLL5ȕ-siRNA therapy can be minimized. It will be interesting to explore the association of MLL5β expression with various stages of cervical carcinoma and the result may lead to a novel biomarker for cervical cancer diagnosis. Moreover, HPV infections are known to associate with other cancers such as head and neck cancer. It will be intriguing to explore whether MLL5ȕ plays a similar role in activating E6/E7 transcription in these HPVrelated cancers. 
AP-1 in HeLa cells (Supplementary
Our current model raised an interesting question of the possible mechanism behind MLL5ȕ derivation. We have tried to map the exact chromosomal location of this 26-bp fragment through bioinformatics search. However, no significant and meaningful sequence match of this 26-bp fragment with HPV genome or human genome can be found. We hypothesized that MLL5ȕ is generated through a more complicated process than simply a result of HPV infection and integration. For instance, DNA double stand break (DSB) repair enzymes are involved in viral integration sites and studies have shown that deficiencies in some DSB repair enzymes caused aberrant junction sequences at the integration sites (38, 39) . This possible aberration adds on difficulty in relying on genomic database to identify the alternative splicing process or design appropriate primers for PCR reactions. In addition, current evidences show that such integration is a random event but common DNA fragile sites are more susceptible to the integration event (40) . If the generation of MLL5ȕ is indeed a result of HPV integration, MLL5 locus is likely located near the common DNA fragile site.
However, it is still difficult to explain how the HPV integration can lead to the same 26-bp at the 3' end of the MLL5ȕ transcript in all 8 primary patient samples (Supplementary Figure   S1 ). We hence suspect that there might be other alternative mechanisms leading to the generation of MLL5ȕ. Based on the fact that the 26bp RNA sequence does not match exactly with any published genomic DNA sequences and this 26-bp lacks the canonical pattern of 3'UTR sequence, RNA editing may be the alternative explanation for such short region modifications in the 3'end of MLL5ȕ RNA (41, 42) . These changes may arise from substitution or insertion/deletion RNA editing; however, more work has to be done to explore the possibility. Author Manuscript Published OnlineFirst on September 9, 2011; DOI: 10.1158/0008-5472. CAN-11-1271 Ubiquitous transcription factors such as AP-1 and SP-1 have well-established roles in HPV transcription regulation (43) (44) (45) . As shown in Figure 6 , the distal region (dashed area) of LCR contains transcription termination signal while the central region (gray area) contains majority of the transcription factor binding sites termed specific enhancer region (46, 47).
The proximal region (chequered area) contains early promoter and origin of replication (48) .
In our study, we identified the distal AP-1 binding site at nucleotide 7326 as the important 
